



Nexstim Receives NBS System 5 Order from a European Distributor

Press release, Helsinki, 30 July 2025 at 9 AM (EEST)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a European distributor.

The end customer is a university hospital in Southern Europe. They are new to Nexstim's navigated transcranial magnetic stimulation (nTMS) technology and will use the system primarily for pre-procedural motor and language mapping in neurosurgery.

The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for pre-operative mapping of the motor and speech cortices of the brain. The information gained from the mapping may be used in pre-procedural planning. This specific system can also be used for rTMS therapy, with a CE mark for the treatment of major depressive disorder and chronic neuropathic pain.

Mikko Karvinen, CEO of Nexstim, comments: *"We are glad to welcome this new customer to our nTMS user community. It is great to see the growing excitement for nTMS in Europe not only for diagnostics but also therapy features."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com